Rachel Fitzpatrick

Rachel Fitzpatrick

Auto-generated profile, based on publicly available information

Rachel Fitzpatrick

School of Medicine, Trinity College Dublin, College Green, Dublin 2, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2024 in BJPsych Open
Verified
Journal Article
Open access
PDF file
EBErin Boland
Erin Boland
RFRachel Fitzpatrick
Rachel Fitzpatrick
DRDearbhail Ryan
Dearbhail Ryan
JKJoseph Kane
Joseph Kane
SBSara Betzhold
Sara Betzhold
IKIrina Kinchin
Irina Kinchin
Background: Lewy body dementia (LBD) is a prevalent yet frequently underdiagnosed form of dementia, accounting for up to 15% of all dementia cases. Aims: This study aims to increase awareness and advocacy for LBD by gathering and critically assessing the economic evidence, including the cost of illness and cost-effectiveness of interventions for managing LBD. Method: A systematic literature review was undertaken with EMBASE, Medline, CINAHL, PsycINFO, NHS Economic Evaluation Database and EconLit. This search was supplemented by grey literature on Google Scholar and reviewing the reference lists of identified studies. The papers included in the review were published between 2008 and 2023, and involved participants with LBD (dementia with Lewy bodies or Parkinson's disease dementia), which either addressed the cost of illness or conducted an economic evaluation. Results: Thirteen papers were included, comprising ten cost-of-illness studies and three economic evaluations. The cost of LBD tends to be higher than that of other forms of dementia, such as Alzheimer's disease, and these costs escalate more steeply as the disease progresses. These cost differences may not be solely influenced by the subtype of dementia, but possibly also by patient characteristics like physical and cognitive abilities. Cost-effectiveness of potential interventions for LBD is limited. Conclusions: Despite numerous drug trials and other interventions for dementia, very few have targeted LBD, let alone explored the cost-effectiveness of such therapies for LBD. This disparity highlights the urgent need for cost-effective strategies and interventions targeting LBD. We propose the establishment of universally accepted standards for LBD research.

11 July 2025 in Alzheimer's & Dementia: Translational Research & Clinical Interventions
Verified
Journal Article
Open access
JKJoseph P. M. Kane
Joseph P. M. Kane
RFRachel L. Fitzpatrick
Rachel L. Fitzpatrick
SBSara Betzhold
Sara Betzhold
GDGillian Daly
Gillian Daly
EKEmily Kalfas
Emily Kalfas
ILIracema College Leroi
Iracema College Leroi
INTRODUCTION: Methodological heterogeneity in dementia with Lewy bodies (DLB) trials contributes to publication bias and makes evidence synthesis and meta‐analysis challenging. We aimed to develop a core outcome set for DLB (DLB COS) trials to improve consistency and comparability in DLB research. METHODS: We conducted a systematic review to identify outcomes and administered a two‐stage Delphi survey to a diverse panel of lay and professional stakeholders. We asked respondents which outcomes should be prioritized and included in DLB COS. RESULTS: Forty‐nine outcomes were presented to survey respondents. Consensus was reached regarding eight outcomes for the final DLB COS: delusions/paranoia; fluctuations in cognition, attention, and arousal; functioning; global cognition; hallucinations; quality of life; motor parkinsonism; and rapid eye movement sleep behavior disorder. DISCUSSION: If adopted, DLB COS can enhance the comparability of research findings and facilitate standardization and harmonization. Highlights: A systematic review revealed heterogeneity in dementia with Lewy bodies (DLB) study outcomes. Our study produced a DLB Core Outcome Set (DLB COS) comprising eight outcomes. DLB COS sets the minimum reporting standards for future trials. DLB‐specific rating scales incorporating these outcomes are needed. Addressing this gap is a strategic priority in DLB research.

24 November 2025 in Brain and Behavior
Verified
Journal Article
Open access
Yaohua Sophie ChenYaohua Sophie Chen
Yaohua Sophie Chen
TMTatyana Mollayeva
Tatyana Mollayeva
RFRachael Fitzpatrick
Rachael Fitzpatrick
TSThaisa Tylinski Sant'ANa
Thaisa Tylinski Sant'ANa
FFFrancesca Farina
Francesca Farina
GPGeeske Peeters
Geeske Peeters
Background: COVID‐19 control measures have had a unique impact on people with dementia (PWD) and their carers living at home. Yet, uncertainty exists regarding the global impact of such measures and whether differences exist between countries and global regions. We aimed to synthesize evidence on this topic. Methods: We searched Medline, PsycINFO, EMBASE, Web of Science, CINAHL, Latin American and Caribbean Health Literature (LILACS), Scientific Electronic Library Online (SciELO), and EM Premium from the start of the pandemic to July 2022. At least two researchers independently screened citations and performed quality assessment following recommended criteria for critical appraisal according to study methodology. We analyzed data by country and region and synthesized results descriptively. Results: Sixty‐nine studies met inclusion criteria (74% quantitative and 26% qualitative; 22% included PWD, 44% carers of PWD, and 4% dyads), with a total of 209,738 participants. Most studies were conducted in Europe (59%), followed by Asia and North America (15% each), South America (7%), and Oceania (1%). Two studies presented data from multiple regions (3%). The quality of the studies varied, with the majority (62%) being of moderate quality. Across the study populations and global regions, COVID‐19 control measures had implications for PWD and carers’ access to health services, physical and mental health and daily routine, cognition, behavior, with accompanying social and economic costs. The impact on mental health for PWD and on loneliness and well‐being for carers were the two most frequently studied outcomes. Conclusion: People with dementia and their carers represent a heterogeneous group of people across countries and communities; despite that, the impacts of COVID‐19 control measures on PWD and their carers were broadly consistent across regions. Our evidence synthesis highlights the critical need for decision‐makers to account for the needs of PWD and their carers when designing and implementing public health measures. Other: This work was funded by the JPND Call for Expert Working Groups: The Impact of COVID‐19 on Neurodegenerative Diseases in partnership with the CIHR‐Institute of Aging and the Public Health Agency (CIHR #02342‐000). PROSPERO CRD42024554701.

18 February 2026 in Social Science & Medicine
Verified
Journal Article
Open access
IKIrina Kinchin
Irina Kinchin
JCJayne Conlon
Jayne Conlon
EBErin Boland
Erin Boland
RFRachel Fitzpatrick
Rachel Fitzpatrick
ILIracema Leroi
Iracema Leroi
JCJoanna Coast
Joanna Coast
Capability measures offer theoretical advantages for assessing wellbeing in health economics and outcomes research, yet their feasibility for self-reporting by people living with dementia remains to be established. This exploratory study compares the feasibility of self-reporting on capability versus health-focused quality of life measures among people living with mild-tomoderate dementia, using response process validation. Twenty-three community-dwelling participants living with Alzheimer's disease (n = 11) or Lewy body dementia (n = 12) completed four measures using concurrent think-aloud cognitive interviewing: two capability measures (ICECAP-O, ICECAP-SCM) and two health-focused measures (QoL-AD, and AQoL-4D). Errors were coded using Tourangeau's four-stage response model (comprehension, retrieval, judgement, response). Completion times, support requirements, and error patterns were compared across measures and diagnostic groups. Capability measures showed higher error rates (13.7-18.3%) than health-related measures (5.1-8.4%) despite shorter completion times. Comprehension errors (51.2% of all errors) were most common across all measures, particularly for abstract concepts like dignity and doing things that make you feel valued. Retrieval errors were rare (4.9%), suggesting memory is not the primary barrier. Diagnostic groups showed distinct error profiles. Participants living with Lewy body dementia showed higher rates of comprehension errors (57.4% vs 42.9%), whilst participants living with Alzheimer's disease showed more response-selection difficulties (25.7% vs 14.9%). While self-reporting remains feasible in mild-to-moderate Alzheimer's disease and Lewy body dementia, capability measures pose greater cognitive demands than health-focused measures, primarily due to comprehension of abstract concepts and distinguishing capability from functioning rather than memory retrieval. Measures should be validated for specific dementia subtypes, and hybrid approaches anchoring capability judgements in concrete experiences warrant exploration. This exploratory study provides preliminary response process validity evidence to inform measure selection in dementia research and clinical practice, ensuring people living with dementia can meaningfully participate in health economics and policy decisions that affect their care.

15 October 2025
Verified
Book Chapter
Closed access
PDF file
BABiniyam A. Ayele
Biniyam A. Ayele
RFRachel Fitzpatrick
Rachel Fitzpatrick
BFBernard Fongang
Bernard Fongang
ILIracema College Leroi
Iracema College Leroi
GPGeeske Peeters
Geeske Peeters
This chapter examines the Nairobi Declaration on Reducing the Burden of Dementia in Low- and Middle-Income Countries (LMICs), which calls for ‘research into affordable, effective solutions to improve dementia care while reducing hospitalization costs and mitigating brain drain by engaging young professionals.’ Although cognitive and neurodegenerative disorders are increasingly recognized as public health priorities in LMICs, local research in these regions is still developing. Local research is essential for addressing the complexities of dementia care within specific contexts, amid a severe shortage of health professionals prepared for this research. This chapter covers three key aspects of capacity and capability development: (1) setting research agendas and prioritizing questions across countries; (2) enhancing African scientists’ expertise and access to research data through the AI-BOND initiative; and (3) best practices for equitable international collaborations in dementia research. <!----> <!----> <!----> <!---->